Antibodies are large proteins utilized by the immune system to fight pathogenic infections.  Since the first therapeutic antibody was approved by the U.S. Food and Drug Administration (FDA) in 1986, the pharmaceutical industry has sought opportunities to leverage antibody technology as therapeutic agents to treat human disease. As of today, the FDA has approved over 25 therapeutic antibody products for use in humans. Global sales of therapeutic antibodies have reached over $40 billion annually and are predicted to remain the fastest growing segment of the therapeutic market.